Keyphrases
Sulfonylurea
100%
Non-insulin-dependent Diabetes Mellitus (NIDDM)
100%
Patients with Cardiovascular Diseases
100%
Ischemia
28%
KATP Channel
28%
Sulfonylurea Derivatives
28%
Beneficial Effects
14%
Ischemia-reperfusion Injury
7%
Clinical Outcomes
7%
Order of Magnitude
7%
Steady State
7%
Ischemic Damage
7%
Europe
7%
Metabolic
7%
B Cells
7%
Clinically Significant
7%
High Dose
7%
Information Transfer
7%
Age Groups
7%
High Incidence
7%
Human Studies
7%
Diabetic
7%
Cardiovascular Mortality
7%
Arrhythmia
7%
Cardiovascular Risk
7%
Cardiovascular Disease
7%
Cardiovascular Function
7%
Opposing Effects
7%
ATP-dependent
7%
Diabetic Patients
7%
Myocardium
7%
Channel Activity
7%
Vascular Tissue
7%
Heart Tissue
7%
Cardiac Effects
7%
Insulin Independence
7%
Clinical Situation
7%
Non-diabetic
7%
Myocardial Injury
7%
Cardioprotection
7%
Atherosclerotic Risk Factors
7%
Advanced Technologies
7%
SUR1
7%
Clinical Decision-making
7%
Complex Events
7%
Prospective Clinical Study
7%
Post-infarction
7%
Direct Action
7%
Non-insulin
7%
Curtailment
7%
Tolbutamide
7%
Recurrent Myocardial Infarction
7%
University Group Diabetes Programme
7%
Oral Antidiabetics
7%
Antidiabetic Treatment
7%
Pharmacology, Toxicology and Pharmaceutical Science
Sulfonylurea
100%
Non Insulin Dependent Diabetes Mellitus
100%
Cardiovascular Disease
100%
Ischemia
35%
Adenosine Triphosphate
35%
Potassium Ion
35%
Sulfonylurea Derivative
28%
Infarction
7%
Diabetes Mellitus
7%
Heart Infarction
7%
Clinical Study
7%
Human Study
7%
Heart Arrhythmia
7%
Cardiovascular Mortality
7%
Antidiabetic Agent
7%
Cardiovascular Risk
7%
Atherosclerosis
7%
Heart Muscle Injury
7%
Tolbutamide
7%
Sulfonylurea Receptor
7%